Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000899243-22-024748
Filing Date
2022-07-01
Accepted
2022-07-01 16:05:15
Documents
1
Period of Report
2022-06-29

Document Format Files

Seq Description Document Type Size
1 FORM 4 SUBMISSION doc4.html 4  
1 FORM 4 SUBMISSION doc4.xml 4 3933
  Complete submission text file 0000899243-22-024748.txt   5343
Mailing Address C/O ACADIA PHARMACEUTICALS INC. 12830 EL CAMINO REAL, SUITE 400 SAN DIEGO CA 92130
Business Address
Ridloff Elena (Reporting) CIK: 0001772518 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-39460 | Film No.: 221061368

Mailing Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472
Business Address 200 ARSENAL YARDS BLVD., SUITE 230 WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Issuer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)